Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 27.
doi: 10.1097/ICO.0000000000004024. Online ahead of print.

Outcome of Cenegermin in the Treatment of Neurotrophic Keratopathy

Golshan Latifi  1   2 , Piseth Dalin Chea  1   3 , Saba Al-Hashimi  1 , Seyed Reza Ghaffari  1 , Anthony J Aldave  1 , Sophie X Deng  1 , Simon S M Fung  1   4
Affiliations

Outcome of Cenegermin in the Treatment of Neurotrophic Keratopathy

Golshan Latifi et al. Cornea. .

Abstract

Purpose: To evaluate the efficacy of cenegermin 0.002% in neurotrophic keratopathy (NK).

Methods: This is a single-center retrospective case series. Data including demographic information, clinical characteristics, and staging of NK at baseline and 8 weeks were collected and analyzed. The primary outcome was improvement in NK 8 weeks after treatment, defined as a reduction in corneal epithelial defect size, or decreased corneal staining score in those without epithelial defect. Secondary outcomes include recurrence and the need for additional intervention.

Results: Fifty-two eyes of 49 patients (mean age 66.0 ± 18.0 years) were included. The mean follow-up was 26.0 ± 16.0 (range 4-51) months. Twenty eyes (38.5%) were classified as Mackie stage 1, 24 (46.2%) as stage 2, and 8 (15.4%) as stage 3 NK. Overall, 67.3% of patients showed improvement by week 8, with resolution of corneal epithelial defect in 62.5% of patients with stage 2 and 3 NK, and a significant decrease in staining score among those with stage 1 disease (2.57 ± 1.07-2.15 ± 1.27, P = 0.002). Multiple logistic regression showed a significant association between Mackie staging and treatment success with cenegermin (OR: 4.79, 95% CI: 1.13-20.26, P = 0.03). Recurrence of NK after cenegermin treatment was observed in 37.5% of eyes within 4 months of follow-up. In patients who received a second course subsequently, 58.3% showed treatment success.

Conclusions: Cenegermin is an effective treatment of NK in the clinical setting, although a notable proportion of patients experience disease recurrence subsequently. Mackie staging is a significant prognostic factor for treatment success.

Keywords: cenegermin; corneal epithelial defect; limbal stem cell deficiency; neurotrophic keratopathy.

PubMed Disclaimer

References

    1. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579.
    1. Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107–131.
    1. Sheha H, Tighe S, Hashem O, et al. Update on cenegermin eye drops in the treatment of neurotrophic keratitis. Clin Ophthalmol. 2019;13:1973–1980.
    1. Hyndiuk RA, Kazarian EL, Schultz RO, et al. Neurotrophic corneal ulcers in diabetes mellitus. Arch Ophthalmol. 1977;95:2193–2196.
    1. Puca A, Meglio M, Vari R, et al. Evaluation of fifth nerve dysfunction in 136 patients with middle and posterior cranial fossae tumors. Eur Neurol. 1995;35:33–37.

LinkOut - more resources